Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

BACKGROUND: Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, was shown to have a clinical benefit in patients with polycythemia vera in a phase 2 study. We conducted a phase 3 open-label study to evaluate the efficacy and safety of ruxolitinib versus standard therapy in patients with polycythemi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:N Engl J Med
Main Authors: Vannucchi, Alessandro M., Kiladjian, Jean Jacques, Griesshammer, Martin, Masszi, Tamas, Durrant, Simon, Passamonti, Francesco, Harrison, Claire N., Pane, Fabrizio, Zachee, Pierre, Mesa, Ruben, He, Shui, Jones, Mark M., Garrett, William, Li, Jingjin, Pirron, Ulrich, Habr, Dany, Verstovsek, Srdan
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4358820/
https://ncbi.nlm.nih.gov/pubmed/25629741
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1409002
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados